487 related articles for article (PubMed ID: 31587172)
1. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
[TBL] [Abstract][Full Text] [Related]
5. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
6. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Shagera QA; Karfis I; Kristanto P; Spyridon S; Diamand R; Santapau A; Peltier A; Roumeguère T; Flamen P; Artigas C
J Nucl Med; 2023 Dec; 64(12):1869-1875. PubMed ID: 37770114
[TBL] [Abstract][Full Text] [Related]
7. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial
Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM
J Nucl Med; 2019 Jul; 60(7):950-954. PubMed ID: 30552200
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Song S; Wang B; Ye D; Hu S
Cancer Med; 2020 May; 9(10):3278-3286. PubMed ID: 32163676
[TBL] [Abstract][Full Text] [Related]
9. Response assessment using [
Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
11. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
12. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of [
Pan J; Zhao J; Ni X; Zhu B; Hu X; Wang Q; Wei Y; Zhang T; Gan H; Wang B; Wu J; Song S; Liu C; Ye D; Zhu Y
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1822-1832. PubMed ID: 36719427
[TBL] [Abstract][Full Text] [Related]
14. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Özülker T; Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
[TBL] [Abstract][Full Text] [Related]
16. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
18. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1276-83. PubMed ID: 25808631
[TBL] [Abstract][Full Text] [Related]
19. [Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
Richter I; Dvořák J; Hejzlarová V; Chalupa J; Sochor M; Stankuš I; Barsová L; Holikova M; Forster J; Bartoš J
Klin Onkol; 2016; 29(2):127-32. PubMed ID: 27081803
[TBL] [Abstract][Full Text] [Related]
20. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Khalaf DJ; Sunderland K; Eigl BJ; Kollmannsberger CK; Ivanov N; Finch DL; Oja C; Vergidis J; Zulfiqar M; Gleave ME; Chi KN
Eur Urol; 2019 Jun; 75(6):940-947. PubMed ID: 30591354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]